3 Stocks Pushing The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 67 points (-0.4%) at 18,405 as of Thursday, July 28, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,296 issues advancing vs. 1,538 declining with 200 unchanged.

The Health Care sector currently sits down 0.1% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the sector include

Mednax

(

MD

), down 7.5%,

Alkermes

(

ALKS

), down 7.4%,

Grifols

(

GRFS

), down 3.8%,

Bristol-Myers Squibb Company

(

BMY

), down 2.0% and

HCA Holdings

(

HCA

), down 1.5%. Top gainers within the sector include

Molina Healthcare

(

MOH

), up 16.9%,

AstraZeneca

(

AZN

), up 7.2%,

Varian Medical Systems

(

VAR

), up 5.8%,

Quintiles Transnational Holdings

(

Q

), up 3.4% and

Centene

(

CNC

), up 3.1%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3.

Shire

(

SHPG

) is one of the companies pushing the Health Care sector lower today. As of noon trading, Shire is down $4.21 (-2.2%) to $190.23 on light volume. Thus far, 693,155 shares of Shire exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $189.72-$193.67 after having opened the day at $193.12 as compared to the previous trading day's close of $194.44.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Shire plc, a biotech company, together with its subsidiaries, engages in the research, development, licensing, manufacture, marketing, distribution, and sale of medicines for patients with rare diseases and other select conditions. Shire has a market cap of $38.2 billion and is part of the drugs industry. Shares are down 5.2% year-to-date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Shire

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Shire Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

AbbVie

(

ABBV

) is down $0.50 (-0.8%) to $64.40 on light volume. Thus far, 3.0 million shares of AbbVie exchanged hands as compared to its average daily volume of 9.1 million shares. The stock has ranged in price between $63.93-$65.06 after having opened the day at $64.79 as compared to the previous trading day's close of $64.90.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $104.2 billion and is part of the drugs industry. Shares are up 9.6% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate AbbVie a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates

AbbVie

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, robust revenue growth, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

AbbVie Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Pfizer

(

PFE

) is down $0.25 (-0.7%) to $36.60 on light volume. Thus far, 5.8 million shares of Pfizer exchanged hands as compared to its average daily volume of 24.8 million shares. The stock has ranged in price between $36.50-$36.91 after having opened the day at $36.88 as compared to the previous trading day's close of $36.85.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $223.4 billion and is part of the drugs industry. Shares are up 14.2% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Pfizer a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Pfizer

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, increase in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Pfizer Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

Loading ...